Best Greeley Grants for Nonprofits in Colorado

The FY26 Melanoma Research Program Survivorship Research Award aims to enhance the well-being of melanoma survivors through innovative research. This funding opportunity supports studies that prioritize quality of life, involving melanoma survivors or their families as collaborators. With approximately $2.04M available, two awards of up to $1.02M each will be granted for research over a maximum period of three years. Applications must be submitted by September 30, 2027, to be funded with FY26 resources.

Community Foundation of Southern New Mexico

Mission: The Community Foundation of Southern New Mexico serves as a community resource, connects donors to needs, and supports charitable organizations in their work.

Scholarships

CFSNM offers scholarships that support students from all walks and stages of life in pursuing various avenues of their educational and professional journeys.

Applicants must be pursuing any avenue of higher education and/or professional certifications. This includes undergraduate, post-grad, vocational and more! Applicants must be actively enrolled as a student. Applicants in high school must be a graduating senior.

Carol Troeller Second Chance Scholarship Fund

To support students with emergency financial needs with a preference for a female student in business fields of study

The FY26 Pancreatic Cancer Research Program (PCARP) Idea Development Award promotes innovative, high-risk research aimed at significant advancements for pancreatic cancer outcomes. This award supports projects with preliminary data, focusing on impactful discoveries. It features a Partnering Principal Investigator option, enhancing funding for collaborations between experienced mentors and early-career researchers. All applications must align with the FY26 PCARP Focus Areas, ensuring relevance and potential for transformative results in pancreatic cancer research.

The FY26 Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award encourages collaboration among clinicians and scientists to expedite the clinical application of innovative pancreatic cancer research. A minimum of two Principal Investigators is required, with one designated as the Initiating PI. This award supports preliminary data collection and various research methodologies, excluding large-scale clinical trials, to enhance pancreatic cancer understanding and treatment.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award supports innovative research aimed at advancing therapies for ALS. It focuses on projects that have demonstrated proof-of-concept efficacy and require lead compounds. The award emphasizes the development of mechanism-specific biomarkers to enhance trial design and patient selection, ensuring that therapeutic approaches are effective and efficient. Collaboration with experienced ALS researchers is encouraged for those with limited experience.

The FY26 Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award supports innovative ideas for ALS drug discovery. This award encourages high-risk, high-gain research that is hypothesis-driven and aims to generate preliminary data for future therapeutic investigations. Applications should highlight potential impact and innovation, with the possibility of achieving results without prior data. The focus is on a strong approach rather than preliminary findings.

The FY26 DoW Pancreatic Cancer Research Program Focused Pilot Award aims to drive innovative and impactful research in pancreatic cancer, enhancing patient quality of life. This award encourages the development of preliminary data to support future clinical or real-world applications. While allowing for clinical research studies, it does not permit clinical trials or preclinical animal studies, ensuring a strong patient-centered approach in its research focus.

The FY26 Amyotrophic Lateral Sclerosis Research Program's Pilot Clinical Trial Award aims to accelerate clinical trials that can significantly impact ALS treatment and management. Focus areas include biomarker-driven interventions and improvements in clinical care. Trials must begin within 12 months of the award and incorporate community collaboration and a detailed regulatory strategy. This award emphasizes the importance of therapeutic interventions and a transition plan for advancing study outcomes beyond the funded work.

The FY26 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) aims to enhance clinical trials for ALS by developing and validating clinical outcomes and biomarkers. This funding opportunity encourages innovative projects that may focus on specific therapies, ALS subtypes, or digital health measures. Collaboration with the ALS community is essential to ensure that research is relevant and informed by lived experiences.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 supports innovative research with the potential for significant breakthroughs in breast cancer. Applications must address key BCRP challenges or justify exceptions, focusing on impactful solutions. This program mandates clinical trials and requires participation from breast cancer consumer advocates. The funding supports single or partnered Principal Investigators, ensuring comprehensive submission processes to avoid administrative withdrawal.

The DoW Ovarian Cancer Academy Early-Career Investigator Award supports junior faculty in conducting innovative ovarian cancer research. Established in FY09, this unique virtual academy fosters mentorship, collaboration, and networking among Early-Career Investigators (ECIs) and their mentors. Participants engage in monthly webinars and annual workshops, enhancing their research skills while contributing to impactful studies in ovarian cancer. The program aims to cultivate a new generation of highly productive researchers in this critical field.

The Ovarian Cancer Clinical Trial Academy (OCCTA) supports Early-Career Investigators (ECIs) in clinical trial research aimed at effective ovarian cancer treatments. It provides essential mentoring, networking, and skill development needed for executing clinical trials. The FY26 funding will specifically support translational research and early-phase trials, requiring preliminary data and a commitment of at least 25% effort from the ECI. Mentorship is vital, with a focus on experienced clinical trialists guiding ECIs.

The DoW Ovarian Cancer Clinical Trial Award, funded by the U.S. Army Medical Command, aims to accelerate the implementation of clinical trials that significantly impact ovarian cancer treatment. This award supports diverse trial designs, from early proof-of-concept studies to large-scale efficacy trials, evaluating innovative drugs, biologics, and technologies. By fostering research in this critical area, the program seeks to enhance patient outcomes and advance the understanding of ovarian cancer management.

The FY26 Breast Cancer Research Program (BCRP) Breakthrough Award Level 3 supports transformative research aimed at significant advancements in breast cancer treatment. Applicants must address key challenges outlined by the program, ensuring their proposals demonstrate potential for impactful breakthroughs. This funding mechanism, which permits small-scale clinical trials, emphasizes collaboration by requiring research teams to include two breast cancer consumer advocates and allows for a single Principal Investigator or two partnering PIs.

The Ovarian Cancer Research Program (OCRP) Investigator-Initiated Research Award aims to support impactful research addressing critical needs in ovarian cancer and patient care. It requires a robust research plan with preliminary data and allows for studies across all research phases, excluding clinical trials. A unique Partnering Principal Investigator option encourages collaboration between two PIs to enhance research outcomes beyond individual efforts, promoting innovation in the field of ovarian cancer.

The DoW Ovarian Cancer Pilot Award fosters innovative research that challenges existing paradigms in ovarian cancer. It aims to propel groundbreaking discoveries and advancements in the field. Notably, the award prioritizes originality over scientific merit alone, ensuring that innovative ideas are at the forefront. The application process includes a blinded pre-application screening to maintain confidentiality and integrity, encouraging fresh perspectives in ovarian cancer research.

The FY26 Breast Cancer Research Program's Transformative Breast Cancer Consortium Award fosters significant collaborations that aim to revolutionize care for individuals affected by breast cancer. This award supports a multidisciplinary consortium of leading scientists, clinicians, and advocates to tackle major challenges in breast cancer research. Proposals must address at least one of the program's overarching challenges and demonstrate a transformative impact that cannot be achieved by individual investigators alone.

Geological Society of America 

The Geological Society of America (GSA), founded in 1888, is a global scientific society with members from academia, government, and industry in more than 100 countries. Through its meetings, publications, and programs, GSA enhances the professional growth of geoscientists at all career levels, encourages cooperative research among earth, life, planetary, and social scientists, fosters public dialogue on geoscience issues, and promotes the geosciences in the service of humankind. GSA is headquartered in Boulder, Colorado, USA.

Jack Kleinman Memorial Award for Volcano Research

The Jack Kleinman Memorial Award for Volcano Research represents a partnership between GSA and the U.S. Geological Survey (USGS) to recognize early-career scientists conducting high-impact research in volcanology. The award was created in memory of Jack Kleinman—a USGS Cascades Volcano Observatory scientist known for his commitment to collecting high-quality field data and who relished a challenge, inspired enthusiasm in others, and delighted in the natural world. The award honors students who demonstrate these same qualities in their scientific explorations.

Up to US$5,000 may be awarded to undergraduate, graduate, and aspiring graduate students, regardless of current enrollment status. Successful proposals typically focus on geologic, geochemical, geophysical, or hazards investigations with an emphasis on fieldwork. Cooperation with a staff member from the USGS Volcano Science Center is encouraged and given considerable weight in the selection process.

Funding is intended to defray the costs of field-focused studies, such as travel to field sites, living expenses during fieldwork, field supplies, and analytical costs. Awardees are invited to present their results in the USGS Kleinman Seminar Series and attend the Awards Ceremony at the GSA annual meeting.

The FY26 Melanoma Research Program Idea Award encourages innovative and high-risk research to advance melanoma treatment. With a budget of approximately $5.6M for 10 awards, each grant can fund up to $0.56M over a maximum of 2 years. The program aims to support projects that establish proof of principle and generate preliminary data for future funding opportunities. Notably, preliminary data is discouraged, and applicants must receive an invitation to submit a full application after the pre-application stage.

About The Children’s Heart Foundation

The Children’s Heart Foundation (CHF) is the country’s leading national organization solely dedicated to funding congenital heart defect (CHD) research. The mission of The Children’s Heart Foundation is to fund the most promising research to advance the diagnosis, treatment, and prevention of congenital heart defects. Since its inception, CHF has funded millions of dollars of CHD research across the U.S. and Canada. 

AHA/CHF Congenital Heart Defect Research Awards

The Children’s Heart Foundation partners with the American Heart Association to fund Congenital Heart Defect Research Awards. This collaborative investment of funds provides support for investigators who are actively conducting research directly related to advancing the prevention, diagnosis, and treatment of CHDs, which directly aligns with The Children's Heart Foundation's mission. 

Congenital Heart Defect Funding Opportunities

A multi-year commitment between the American Heart Association (AHA) and Children’s Heart Foundation (CHF) jointly supports Predoctoral Fellowship or Postdoctoral Fellowship investigators actively conducting basic, clinical, population, or translational congenital heart defects research.

Predoctoral Fellowship

Purpose

To enhance the integrated research and clinical training of promising students who are matriculated in pre-doctoral or clinical health professional degree training programs and who intend careers as scientists, physician-scientists or other clinician-scientists, or related careers aimed at improving global cardiovascular, cerebrovascular and brain health.

• AHA research awards are limited to U.S.-based non-profit institutions, including medical, osteopathic, and dental schools, veterinary schools, schools of public health, pharmacy schools, nursing schools, universities and colleges, public and voluntary hospitals and others that can demonstrate the ability to conduct the proposed research.

• Applicants must be AHA Professional Members at the time of proposal submission. The AHA expects all mentors associated with training/mentored research awards to maintain active AHA membership, as well.

• This award is not for individuals of faculty/staff rank.

Applicants are not required to reside in the United States for any period before applying for American Heart Association funding. However, applicants must have one of the following designations at the time of proposal submission – not award start date, depending on career stage and each individual’s situation. An awardee must maintain one of the designations listed below throughout the duration of the award. Please consult with your institution’s grant officer.

• U.S. citizen
• Permanent resident
• Pending permanent resident (must have filed Form I-485 for permanent resident status and obtained an I-797C 3 Notice of Action that the application has been received by USCIS and case is pending)
• E-3 Visa - specialty occupation worker
• F-1 Visa – student (for predoctoral and postdoctoral fellows only)
• G-4 Visa - family member of an international organization employee
• H1-B Visa - temporary worker in a specialty occupation
• J-1 Visa - exchange visitor (pre- and postdoctoral fellowships only; all other awardees must obtain an H-1B or equivalent by the award activation date)
• O-1 Visa - temporary worker with extraordinary abilities in the sciences
• TN Visa - NAFTA Professional
• DACA - Deferred Action for Childhood Arrivals

About The Children’s Heart Foundation

The Children’s Heart Foundation (CHF) is the country’s leading national organization solely dedicated to funding congenital heart defect (CHD) research. The mission of The Children’s Heart Foundation is to fund the most promising research to advance the diagnosis, treatment, and prevention of congenital heart defects. Since its inception, CHF has funded millions of dollars of CHD research across the U.S. and Canada. 

AHA/CHF Congenital Heart Defect Research Awards

The Children’s Heart Foundation partners with the American Heart Association to fund Congenital Heart Defect Research Awards. This collaborative investment of funds provides support for investigators who are actively conducting research directly related to advancing the prevention, diagnosis, and treatment of CHDs, which directly aligns with The Children's Heart Foundation's mission. 

Congenital Heart Defect Funding Opportunities

A multi-year commitment between the American Heart Association (AHA) and Children’s Heart Foundation (CHF) jointly supports Predoctoral Fellowship or Postdoctoral Fellowship investigators actively conducting basic, clinical, population, or translational congenital heart defects research.

Postdoctoral Fellowship

Purpose

To enhance the training of postdoctoral applicants who are not yet independent. The applicant must be embedded in an appropriate investigative group with the mentorship, support, and relevant scientific guidance of a research mentor. Recognizing the unique challenges that clinicians, in particular, experience in balancing research and clinical activity, this award mechanism aims to be as flexible as possible to enable applicants to develop academic careers in research alongside fulfilling clinical service commitments.

The trainee and mentor should collaboratively provide a thoughtfully planned, systematic proposal aimed at clearly answering an investigative question in cardiovascular, cerebrovascular or brain health research

• AHA research awards are limited to U.S.-based non-profit institutions, including medical, osteopathic, and dental schools, veterinary schools, schools of public health, pharmacy schools, nursing schools, universities and colleges, public and voluntary hospitals andothers that can demonstrate the ability to conduct the proposed research.

• Applicants must be AHA Professional Members at the time of proposal submission. The AHA expects all mentors associated with training/mentored research awards to maintain active AHA membership, as well.

• This award is not intended for individuals of faculty rank.

Applicants are not required to reside in the United States for any period before applying for American Heart Association funding. However, applicants must have one of the following designations at the time of proposal submission – not award start date, depending on career stage and each individual’s situation. An awardee must maintain one of the designations listed below throughout the duration of the award. Please consult with your institution’s grant officer.

• U.S. citizen
• Permanent resident
• Pending permanent resident (must have filed Form I-485 for permanent resident status and obtained an I-797C 3 Notice of Action that the application has been received by USCIS and case is pending)
• E-3 Visa - specialty occupation worker
• F-1 Visa – student (for predoctoral and postdoctoral fellows only)
• G-4 Visa - family member of an international organization employee
• H1-B Visa - temporary worker in a specialty occupation
• J-1 Visa - exchange visitor (pre- and postdoctoral fellowships only; all other awardees must obtain an H-1B or equivalent by the award activation date)
• O-1 Visa - temporary worker with extraordinary abilities in the sciences
• TN Visa - NAFTA Professional
• DACA - Deferred Action for Childhood Arrivals

The FY26 Peer Reviewed Cancer Research Program's Idea Award promotes innovative, high-risk cancer research initiatives. It supports groundbreaking concepts that advance cancer knowledge, patient care, and treatment options within the Military Health System. Projects must demonstrate creativity and innovation, avoiding incremental advancements. Notably, the Early Career Investigator Option is available to foster the growth of promising new investigators early in their careers. This award aims to make significant contributions to cancer research for Service Members and Veterans.

The DoW Peer Reviewed Cancer Clinical Trial Award supports the rapid initiation of clinical trials aimed at significantly improving cancer treatment. Projects may range from small pilot studies to large-scale phase III trials, focusing on innovative products, drugs, or devices. This award mandates the inclusion of patient advocates and prohibits animal studies, ensuring that all preclinical work is completed prior to the award start date. Regulatory applications must be submitted if required for the proposed trials.

The FY26 Peer Reviewed Cancer Research Program Impact Award promotes significant research aimed at enhancing clinical cancer care. It requires preliminary data to ensure feasibility and emphasizes projects with a strong potential for immediate impact. This funding supports clinical trials and allows for either a single Principal Investigator or a duo of partnering PIs, ensuring that both can contribute distinct aspects of the research. Applications must be carefully coordinated to avoid withdrawal risks.

The FY26 Traumatic Brain Injury and Psychological Health Research Program's Clinical Trial Award aims to fund impactful clinical trials that address psychological health issues and traumatic brain injury (TBI). This award supports a variety of interventions, requires preliminary data, and mandates community-based participatory research approaches. It offers two research levels: one for pilot studies and early trials, and another for larger, advanced trials assessing effectiveness in relevant populations.

The FY26 Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) aims to support impactful health services research that connects research, practice, and policy. It emphasizes building real-world evidence for interventions and clinical guidelines tailored to specific populations. Key features include requirements for clinical trials, preliminary data, and community-based participatory research approaches. The program also offers an Early-Career Investigator Partnering Option to foster collaboration between seasoned and emerging researchers.